Assenagon Asset Management’s Evoqua Water Technologies Corp. Common Stock AQUA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-2,552,685
Closed -$127M 1510
2023
Q1
$127M Buy
2,552,685
+2,306,086
+935% +$108M 0.45% 45
2022
Q4
$9.77M Buy
246,599
+236,852
+2,430% +$9.31M 0.04% 383
2022
Q3
$322K Sell
9,747
-173,026
-95% -$6.28M ﹤0.01% 1192
2022
Q2
$5.94M Buy
182,773
+54,656
+43% +$2.08M 0.02% 490
2022
Q1
$6.02M Sell
128,117
-277,056
-68% -$11.8M 0.02% 490
2021
Q4
$18.9M Buy
405,173
+226,910
+127% +$9.87M 0.05% 219
2021
Q3
$6.7M Buy
178,263
+69,511
+64% +$2.51M 0.02% 352
2021
Q2
$3.67M Sell
108,752
-395,069
-78% -$11.9M 0.01% 549
2021
Q1
$13.3M Buy
503,821
+24,393
+5% +$650K 0.05% 287
2020
Q4
$12.9M Buy
479,428
+357,138
+292% +$8.86M 0.06% 211
2020
Q3
$2.6M Buy
+122,290
New +$2.44M 0.01% 526

Other funds holding AQUA

Assenagon Asset Management's AQUA Position: Q2 2023 in Review

Assenagon Asset Management sold out of Evoqua Water Technologies Corp. Common Stock (AQUA) in Q2 2023, closing a stake of 2,552,685 shares — an estimated $127M sold.

Assenagon Asset Management first reported a position in AQUA in Q3 2020 and held it in 11 quarters. The position peaked at $127M in Q1 2023. 1 fund tracked by Wall St. Rank holds AQUA as of Q2 2023.

  • Assenagon Asset Management reported no remaining Evoqua Water Technologies Corp. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 2,552,685 Evoqua Water Technologies Corp. Common Stock shares in Q2 2023, an estimated $127M.
  • Assenagon Asset Management first reported a position in Evoqua Water Technologies Corp. Common Stock in Q3 2020 and held it in 11 quarters.
  • Assenagon Asset Management's Evoqua Water Technologies Corp. Common Stock position peaked at $127M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Evoqua Water Technologies Corp. Common Stock as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.